Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:INVANASDAQ:MNKDNASDAQ:MYGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$19.49-1.8%$18.87$14.40▼$47.00$1.29B1.39909,231 shs923,822 shsINVAInnoviva$19.64+0.8%$18.32$15.56▼$21.28$1.23B0.35642,957 shs872,004 shsMNKDMannKind$4.16+1.0%$4.64$4.05▼$7.63$1.26B1.142.37 million shs2.47 million shsMYGNMyriad Genetics$4.18+0.5%$6.58$3.81▼$29.30$385.30M2.011.17 million shs2.42 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics0.00%-4.23%-5.66%+0.72%-41.47%INVAInnoviva0.00%+3.53%+4.91%+10.40%+24.38%MNKDMannKind0.00%+0.97%-16.80%-18.91%-10.92%MYGNMyriad Genetics0.00%+6.91%-44.71%-59.77%-81.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.9347 of 5 stars4.50.00.00.03.40.00.0INVAInnoviva4.4749 of 5 stars3.51.00.04.23.72.51.9MNKDMannKind2.8797 of 5 stars3.61.00.00.02.81.71.9MYGNMyriad Genetics3.8142 of 5 stars4.01.00.04.11.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90176.55% UpsideINVAInnoviva 3.00Buy$55.00180.04% UpsideMNKDMannKind 3.25Buy$10.00140.38% UpsideMYGNMyriad Genetics 2.06Hold$14.79253.73% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, CLDX, MNKD, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.005/7/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.005/7/2025MYGNMyriad GeneticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M171.16N/AN/A$9.08 per share2.15INVAInnoviva$369.84M3.33$3.80 per share5.17$10.66 per share1.84MNKDMannKind$297.60M4.25N/AN/A($0.91) per share-4.57MYGNMyriad Genetics$831.30M0.46N/AN/A$9.53 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/14/2025 (Estimated)INVAInnoviva$179.72M-$1.0128.4612.67N/A18.31%20.84%11.38%7/29/2025 (Estimated)MNKDMannKind-$11.94M$0.1059.4318.09N/A8.07%-17.74%8.68%8/6/2025 (Estimated)MYGNMyriad Genetics-$263.30M-$1.12N/AN/AN/A-14.09%-4.51%-3.07%8/5/2025 (Estimated)Latest MYGN, CLDX, MNKD, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27INVAInnoviva0.381.791.64MNKDMannKindN/A4.544.17MYGNMyriad Genetics0.051.901.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%MNKDMannKind49.55%MYGNMyriad Genetics99.02%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%INVAInnoviva2.25%MNKDMannKind2.70%MYGNMyriad Genetics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableINVAInnoviva10062.78 million61.54 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableMYGNMyriad Genetics2,60092.18 million89.12 millionOptionableMYGN, CLDX, MNKD, and INVA HeadlinesRecent News About These CompaniesWellington Management Group LLP Decreases Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)May 30 at 5:52 AM | marketbeat.comVoloridge Investment Management LLC Makes New $1.64 Million Investment in Myriad Genetics, Inc. (NASDAQ:MYGN)May 30 at 4:03 AM | marketbeat.comMyriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025May 27, 2025 | insidermonkey.comMyriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025May 27, 2025 | msn.comMyriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comLevi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities FraudMay 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities InvestigationMay 27, 2025 | accessnewswire.comSpotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1May 27, 2025 | finance.yahoo.comBronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to ConnectMay 26, 2025 | accessnewswire.comLevi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities FraudMay 25, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach OutMay 25, 2025 | accessnewswire.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives $15.79 Consensus Price Target from AnalystsMay 24, 2025 | americanbankingnews.comATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About InvestigationMay 23, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the InvestigationMay 23, 2025 | accessnewswire.comScotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector PerformMay 23, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Cut to "Sector Perform" at ScotiabankMay 23, 2025 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from BrokeragesMay 23, 2025 | marketbeat.comScotiabank cuts Myriad Genetics stock rating, slashes price targetMay 22, 2025 | uk.investing.comFraud Investigation Opened: Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) on Behalf of ShareholdersMay 22, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the InvestigationMay 22, 2025 | accessnewswire.comPoint72 Asset Management L.P. Sells 715,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)May 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, CLDX, MNKD, and INVA Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$19.49 -0.35 (-1.76%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$19.78 +0.29 (+1.49%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$19.64 +0.15 (+0.77%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$19.57 -0.07 (-0.36%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$4.16 +0.04 (+0.97%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$4.15 -0.01 (-0.24%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Myriad Genetics NASDAQ:MYGN$4.18 +0.02 (+0.48%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$4.19 +0.01 (+0.24%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
